Form 8-K

8-K — RELMADA THERAPEUTICS, INC.

Accession: 0001213900-26-082007

Filed: 2026-07-28

Period: 2026-07-28

CIK: 0001553643

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0299449-8k_relmada.htm (Primary)

EX-99.1 — PRESS RELEASE ISSUED ON JULY 28, 2026 (ea029944901ex99-1.htm)

GRAPHIC (ea029944901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0299449-8k_relmada.htm · Sequence: 1

false

0001553643

2026-07-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported): July

28, 2026

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-39082

45-5401931

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2222 Ponce de Leon Blvd., Floor 3

Coral Gables, FL

33134

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (786) 629-1376

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, $0.001 par value per share

RLMD

Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 28, 2026, Relmada

Therapeutics, Inc. (the “Company”), issued a press release announcing the appointment of Bipin Dalmia, PhD, MBA as the Company’s

Chief Business. Pursuant to Regulation FD, the press release is furnished with this Current Report as Exhibit 99.1.

The information set

forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall

not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on

Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities

Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements

and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1*

Press release issued on July 28, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

This Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 28, 2026

RELMADA THERAPEUTICS, INC.

By:

/s/ Sergio Traversa

Name:

Sergio Traversa

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE ISSUED ON JULY 28, 2026

EX-99.1

Filename: ea029944901ex99-1.htm · Sequence: 2

Exhibit 99.1

Relmada Therapeutics Appoints Uro-Oncology Leader

Bipin Dalmia as Chief Business Officer

● Brings

nearly three decades of leadership spanning NMIBC, corporate strategy and business development

to help advance NDV-01 and support the Company’s long-term growth and value creation.

CORAL GABLES, FL – July 28, 2026 (GlobeNewswire) –

Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company

advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia,

PhD, MBA, as Chief Business Officer. Bipin will lead Relmada’s corporate strategy, commercial planning, and business development activities,

reporting directly to Chief Executive Officer Sergio Traversa.

Bipin Dalmia joins Relmada with nearly three decades

of biopharmaceutical leadership, combining extensive experience in corporate strategy and business development with deep expertise in

non-muscle invasive bladder cancer (NMIBC). As the Company advances NDV-01, its novel sustained-release intravesical therapy for patients

with NMIBC, Bipin’s appointment reflects Relmada’s rapid evolution toward late-stage development and its commitment to building

the commercial and strategic capabilities needed to maximize the value of NDV-01.

“Bipin combines a deep understanding of the

evolving NMIBC treatment and competitive landscape, with exceptional experience in helping bring the first FDA-approved intravesical gene

therapy to bladder cancer patients. His experience and perspective will be invaluable in helping us maximize the clinical, commercial

and long-term potential of NDV-01,” said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics. “In addition

to advancing NDV-01, Bipin’s experience in corporate strategy, business development and value creation will strengthen Relmada as we evaluate

opportunities to maximize long-term shareholder value.”

“I am excited to join Relmada at such an

important stage in the Company’s evolution. What drew me to this opportunity was the chance to help realize the full potential of NDV-01.

The NMIBC treatment landscape is entering a period of rapid innovation, yet patients continue to face significant unmet needs. NDV-01’s

differentiated product profile and encouraging clinical data generated to date position it to become a best-in-class intravesical therapy

across the NMIBC disease spectrum,” said Bipin Dalmia, Chief Business Officer. “I look forward to working alongside the

outstanding Relmada team to help advance the next phase of NDV-01’s development and, if successful, bring this innovative therapy to patients

as quickly as possible.”

About Bipin Dalmia, PhD, MBA

Bipin Dalmia is a senior biopharmaceutical executive

with nearly three decades of leadership roles across corporate strategy, portfolio management, commercial planning, business development

and M&A in biotechnology, specialty pharmaceuticals, and global pharmaceutical companies.

Most recently, he served as Senior Vice President,

Global Head of Portfolio Strategy & Business Development at Ferring Pharmaceuticals, where he established and led this new global

function. During his 14-year tenure at Ferring, in addition to global business development leadership, he led the company’s Uro-Oncology

Franchise, including the U.S. launch and global lifecycle and manufacturing strategy for ADSTILADRIN® – the first FDA-approved

intravesical gene therapy for BCG-unresponsive NMIBC patients. Beyond ADSTILADRIN, Bipin led and completed more than 20 strategic licensing,

partnership and M&A transactions across multiple therapeutic areas, modalities and development stages, while strengthening the company’s

portfolio management and capital allocation capabilities.

Prior to Ferring, Bipin held business development

leadership positions at Biolex Therapeutics and earlier served in strategy, new product planning and business development roles at Syngenta

and Novartis. He began his career as a research scientist. He currently serves on the Board of Directors of Ferring Ventures S.A. and

on the Board of Directors of FinVector Oy.

Bipin Dalmia holds a PhD and an MS in Chemical

Engineering from Iowa State University and an MBA from Drake University.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology

company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01

and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Forward-Looking Statements:

The Private Securities Litigation Reform Act of

1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute

“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of

words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”,

“will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”,

and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number

of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking

statements, including potential for Relmada’s product candidates to fail to progress, potential for Phase 2 NDV-01 data to fail

to continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically

and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete

results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure

to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone clinical

results will be acceptable to the FDA, failure to secure adequate NDV-01 and/or sepranolone drug supply, failure of pending patent applications

to result in issued patents, or issued patents being challenged and invalidated by third parties or not providing us with any competitive

advantages, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating

the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including

clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports

filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those

projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,

future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other

factors that may affect future results and that the risks described herein are not a complete list.

Investor Contact:

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications

media@relmada.com

GRAPHIC

Filename: ea029944901_ex99-1img1.jpg · Sequence: 3

Binary file (17367 bytes)

Download ea029944901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 28, 2026

Entity File Number

001-39082

Entity Registrant Name

RELMADA THERAPEUTICS, INC.

Entity Central Index Key

0001553643

Entity Tax Identification Number

45-5401931

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2222 Ponce de Leon Blvd.

Entity Address, Address Line Two

Floor 3

Entity Address, City or Town

Coral Gables

Entity Address, State or Province

Entity Address, Postal Zip Code

33134

City Area Code

786

Local Phone Number

629-1376

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value per share

Trading Symbol

RLMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration